Deutsche Wohnen SE

  • WKN: A0HN5C
  • ISIN: DE000A0HN5C6
  • Land: Deutschland

Analyst Coverage

Datum Institute Analyst Rating Target Price (EUR)
25/11/2021 M. M. Warburg Simon Stippig sell 51,25
15/11/2021 Kepler Cheuvreux Thomas Neuhold hold 49,50
15/11/2021 Oddo BHF Manuel Martin neutral 45,00
12/11/2021 Alpha Value Christian Auzanneau add 52,50
06/10/2021 RBC Jonathan Livingston-Booth sector perform 53,00
22/09/2021 Exane BNP Paribas Rob Jones neutral 53,00
20/09/2021 Independent Research Jan Lennertz hold 53,00
13/08/2021 Barclays Sander Bunck overweight 55,00
13/08/2021 Berenberg Bank Kai Klose buy 55,00
13/08/2021 Kempen Jaap Kuin neutral 52,00
13/08/2021 LBBW Jürgen Graf sell 53,00
13/08/2021 Nord LB Michael Seufert accept offer 53,00
23/06/2021 DZ Bank AG Research Karsten Oblinger hold 52,50
01/06/2021 Jefferies Thomas Rothäusler hold 53,00
26/05/2021 Commerzbank Tom Carstairs hold 56,00
18/05/2021 Goldman Sachs Jonathan Kownator hold 49,00
12/05/2021 Bank of America Merrill Lynch Marc Mozzi buy 58,00
12/05/2021 J.P. Morgan Cazenove Neil Green overweight 51,00
12/05/2021 Morgan Stanley Bart Gysens overweight 48,00

GBC im Fokus

IGEA Pharma N.V. Realignment to CBD extraction

The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.

News im Fokus

Vonovia SE: Vorstandsmitglieder von Vonovia werden ihre Bezugsrechte ausüben

30. November 2021, 16:02

Aktueller Webcast

HelloFresh SE

Capital Markets Day

08. Dezember 2021

Aktuelle Research-Studie

clearvise AG

Original-Research: clearvise AG (von First Berlin Equity Research GmbH): Buy

30. November 2021